Ruth Payne
A5083590098- Malaria Research and Control
- SARS-CoV-2 and COVID-19 Research
- Mosquito-borne diseases and control
- COVID-19 Clinical Research Studies
- vaccines and immunoinformatics approaches
- Complement system in diseases
- Long-Term Effects of COVID-19
- Hepatitis B Virus Studies
- Immunotherapy and Immune Responses
- Influenza Virus Research Studies
- HIV Research and Treatment
- Poverty, Education, and Child Welfare
- Ethics in Clinical Research
- Vaccine Coverage and Hesitancy
- Children's Rights and Participation
- Computational Drug Discovery Methods
- Intensive Care Unit Cognitive Disorders
- T-cell and B-cell Immunology
- Herpesvirus Infections and Treatments
- Respiratory viral infections research
- Ethics in medical practice
- Immune Cell Function and Interaction
- Viral Infections and Vectors
- Autism Spectrum Disorder Research
- Disaster Response and Management
Jenner Institute
2013-2025
University of Oxford
2015-2025
University of Sheffield
2020-2025
Sheffield Teaching Hospitals NHS Foundation Trust
2021-2025
Northern General Hospital
2025
Western Kentucky University
2024
University of Leeds
2015-2023
Hospital for Tropical Diseases
2016
National Institute for Health Research
2015
Oxford Biomedical Research
2015
The West African outbreak of Ebola virus disease that peaked in 2014 has caused more than 11,000 deaths. development an effective vaccine is a priority for control future outbreak.
BackgroundDevelopment of an effective vaccine against the pathogenic blood-stage infection human malaria has proved challenging, and no candidate affected parasitemia following controlled (CHMI) with Plasmodium falciparum.MethodsWe undertook a phase I/IIa clinical trial in healthy adults United Kingdom RH5.1 recombinant protein vaccine, targeting P. falciparum reticulocyte-binding homolog 5 (RH5), formulated AS01B adjuvant. We assessed safety, immunogenicity, efficacy CHMI. Trial registered...
Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine immunogenicity varies between individuals, and immune responses correlate with efficacy. Using data from 1,076 participants enrolled in ChAdOx1 nCov-19 efficacy trials the United Kingdom, we found that inter-individual variation normalized antibody against SARS-CoV-2 spike its receptor-binding domain (RBD) at 28 days after first vaccination shows genome-wide significant association major histocompatibility complex...
Click to increase image sizeClick decrease size Notes This editorial and most articles in this special issue use the terms children, youth young people interchangeably refer under age of 25 years (United Nations 1989 United Nations, 1989. Convention on Rights Child [online]. Available from: http://www.unchchr.ch/html/menu3/b/k2crc.htm [Accessed 17 December 2002]. [Google Scholar]). The seeds for were sown some time back at a seminar hosted by Centre Child-Focussed Anthropological Research...
Highlights•Human PfRH5 vaccination induces cross-reactive neutralizing antimalarial antibodies•Neutralizing human antibodies bind epitopes close to the basigin binding site•Some non-neutralizing potentiate those several malaria proteins•Potentiating slow erythrocyte invasion by a new epitope on PfRH5SummaryThe Plasmodium falciparum reticulocyte-binding protein homolog 5 (PfRH5) is leading target for next-generation vaccines against disease-causing blood-stage of malaria. However, little...
The development of a highly effective vaccine remains key strategic goal to aid the control and eventual eradication Plasmodium falciparum malaria. In recent years, reticulocyte-binding protein homolog 5 (RH5) has emerged as most promising blood-stage P. candidate antigen date, capable conferring protection against stringent challenge in Aotus monkeys. We report on first clinical trial our knowledge assess RH5 — dose-escalation phase Ia study 24 healthy, malaria-naive adult volunteers....
BackgroundT-cell responses against highly conserved influenza antigens have been previously associated with protection. However, these immune are poorly maintained following recovery from infection and not boosted by inactivated vaccines. We demonstrated the safety immunogenicity of two viral vectored vaccines, modified vaccinia virus Ankara (MVA) chimpanzee adenovirus ChAdOx1 expressing antigens, nucleoprotein (NP) matrix protein-1 (M1). now report on long-term multiple combination regimes...
Background. Models of controlled human malaria infection (CHMI) initiated by mosquito bite have been widely used to assess efficacy preerythrocytic vaccine candidates in small proof-of-concept phase 2a clinical trials. Efficacy testing blood-stage parasite vaccines, however, has generally relied on larger-scale 2b field trials malaria-endemic populations. We report the use a P. falciparum CHMI model candidates, using their impact multiplication rate (PMR) as primary end point. Methods....
Plasmodium vivax is the most widespread human malaria geographically; however, no effective vaccine exists. Red blood cell invasion by P. merozoite depends on an interaction between Duffy antigen receptor for chemokines (DARC) and region II of parasite's Duffy-binding protein (PvDBP_RII). Naturally acquired binding-inhibitory antibodies against this associate with clinical immunity, but it unknown whether these responses can be induced vaccination.Safety immunogenicity replication-deficient...
Background. The need for a highly efficacious vaccine against Plasmodium falciparum remains pressing. In this controlled human malaria infection (CHMI) study, we assessed the safety, efficacy and immunogenicity of schedule combining 2 distinct types in staggered immunization regimen: one inducing high-titer antibodies to circumsporozoite protein (RTS,S/AS01B) other potent T-cell responses thrombospondin-related adhesion (TRAP) by using viral vector. Method. Thirty-seven healthy malaria-naive...
RH5 is a leading blood-stage candidate antigen for Plasmodium falciparum vaccine; however, its safety and immunogenicity in malaria-endemic populations are unknown.
Abstract Child-headed households (CHHs), in which adults or guardians are either absent not fully functioning terms of providing for the material and emotional needs children, have been largely explored through a coping strategies approach. These studies emphasise ability children young people to exert agency face adversity, typically casting them as extraordinary survivors. This perspective continues drive social interventions with CHHs, take less account how themselves make sense their...
Plasmodium falciparum reticulocyte-binding protein homolog 5 (PfRH5) is a leading asexual blood-stage vaccine candidate for malaria. In preparation clinical trials, full-length PfRH5 called "RH5.1" was produced as soluble product under cGMP using the ExpreS2 platform (based on Drosophila melanogaster S2 stable cell line system). Following development of high-producing monoclonal line, master bank prior to campaign. Culture supernatants were processed C-tag affinity chromatography followed by...
To prepare for potential human infection challenge studies (HICS) involving SARS-CoV-2, we convened a multidisciplinary working group to address ethical questions regarding whether and how much SARS-CoV-2 HICS participants should be paid. Because the goals of paying participants, as well relevant concerns, are same those arising other types clinical research, basic framework payment can apply. This divides into reimbursement, compensation, incentives, focusing on fairness promoting adequate...
Interactions between B cells and CD4+ T follicular helper (Tfh) are key determinants of humoral responses. Using samples from clinical trials performed with the malaria vaccine candidate antigen Plasmodium falciparum merozoite protein (PfRH5), we compare frequency, phenotype, gene expression profiles PfRH5-specific circulating Tfh (cTfh) elicited by two leading human delivery platforms: heterologous viral vector prime boost AS01B adjuvant. We demonstrate that protein/AS01B platform induces a...
Modifications to vaccine delivery that increase serum antibody longevity are of great interest for maximizing efficacy. We have previously shown a delayed fractional (DFx) dosing schedule (0-1-6 month) - using AS01B-adjuvanted RH5.1 malaria antigen substantially improves IgG durability as compared with monthly (0-1-2 month; NCT02927145). However, the underlying mechanism and whether there wider immunological changes DFx were unclear. Here, PfRH5-specific Ig B cell responses analyzed in depth...
We assessed a combination multi-stage malaria vaccine schedule in which RTS,S/AS01B was given concomitantly with viral vectors expressing multiple-epitope thrombospondin-related adhesion protein (ME-TRAP) 0-month, 1-month, and 2-month schedule. as either three full doses or fractional (1/5th) third dose. Efficacy by controlled human infection (CHMI). Safety immunogenicity of the regimen also assessed. Forty-one malaria-naive adults received at 0, 4 8 weeks, alone (Groups 1 2) ChAd63 ME-TRAP...
Obsessive-compulsive disorder (OCD) in young people can be effectively treated with Cognitive Behavior Therapy (CBT). Practice guidelines the United Kingdom recommend that CBT delivered parental or family involvement; however, there is no evidence from randomized trials this enhances effectiveness. The aim of trial was to assess if high involvement more effective than low (individual CBT) reducing symptoms OCD.Fifty ages 12-17 years OCD were randomly allocated individual parent-enhanced CBT....
The use of systems rewards and sanctions within behaviour policies has now been adopted formally in UK schools. Such potentially represent competing theoretical ideas when considered alongside current approaches to teaching learning. There is also opportunity for inconsistent resulting from the absence a distinction between incentives punishments again pupils' task-based work their social behaviour. This case study comprises one three questionnaire surveys completed by secondary school...
Background Transmission blocking vaccines targeting the sexual-stages of malaria parasite could play a major role to achieve elimination and eradication malaria. The Plasmodium falciparum Pfs25 protein (Pfs25) is most clinically advanced candidate sexual-stage antigen. IMX313, complement inhibitor C4b-binding that forms heptamers with antigen fused it, improve antibody responses. This first time viral vectors have been used induce antibodies in humans against an expressed only mosquito...
Falciparum malaria is clinically heterogeneous and the relative contribution of parasite host in shaping disease severity remains unclear. We explored interaction between inflammation variant surface antigen (VSA) expression, asking whether this relationship underpins variation observed controlled human infection (CHMI). uncovered marked heterogeneity response to blood challenge; some volunteers remained quiescent, others triggered interferon-stimulated showed transcriptional evidence...